Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Bone Marrow Transplantation (83)
Leukemia (32)
British Journal of Cancer (6)
Nature (4)
Nature Communications (2)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (90)
Correspondence (15)
Special Features (10)
Reviews (8)
Comments & Opinion (6)
Amendments and Corrections (3)
News & Views (3)

Subject Check one or more subjects to show results from those subjects only.

Biomarkers
Cancer
Cell biology
Chemical biology
Chemistry
Diseases
Drug discovery
Evolution
Genetics
Health care
Immunology
Materials science
Medical research
Microbiology
Oncology
Scientific community
Stem cells

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–50 of 135 results

Advanced filters: Author: J. F. Apperley Clear advanced filters

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies

SARS-CoV-2 vaccination has shown reduced efficacy in patients with haematological malignancies. Here, the authors show that a third vaccine is able to enhance SARS-CoV-2 antibody responses in most cases in a cohort of 381 patients with haematological malignancies.

Lucy B. Cook
Gillian O’Dell
Andrew J. Innes
ResearchOpen Access14 Nov 2022
Nature Communications

Volume: 13, P: 1-6
Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow

S. D. Patterson
A. Gottschalk
I. Roeder
ResearchOpen Access07 Jan 2026
Leukemia

P: 1-5
Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

F van Rhee
RM Szydlo
A Gratwohl
Research01 Oct 1997
Bone Marrow Transplantation

Volume: 20, P: 553-560
Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

DE Speiser
J Hermans
JF Apperley
Research01 Jun 1997
Bone Marrow Transplantation

Volume: 19, P: 1197-1203
Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma

Carmen Rivas
Phil Chandler
Jane F Apperley
Research15 Jun 2000
Cancer Gene Therapy

Volume: 7, P: 954-962
Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia

Explosive growth is attributed to the BCR::ABL1 gene 3–14 years before diagnosis of chronic myeloid leukaemia, highlighting the oncogenic potency of gene fusion and the slow and sequential trajectories of most other cancers.

Aleksandra E. Kamizela
Daniel Leongamornlert
Jyoti Nangalia
ResearchOpen Access09 Apr 2025
Nature

Volume: 640, P: 982-990
Syngeneic transplantation in multiple myeloma – a case-matched comparison with autologous and allogeneic transplantation

G Gahrton
H Svensson
J Wallvik
Research30 Sept 1999
Bone Marrow Transplantation

Volume: 24, P: 741-745
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors

F van Rhee
D Savage
JM Goldman
Research14 May 1998
Bone Marrow Transplantation

Volume: 21, P: 1055-1061
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels

EJ Kanfer
D McGuigan
ES Newlands
Research01 Oct 1998
British Journal of Cancer

Volume: 78, P: 928-932
Microwaves effectively examine the extent and type of coking over acid zeolite catalysts

Catalyst deactivation by coke deposition is a major drawback in industrial processes. Here, the authors show a non-intrusive microwave cavity perturbation technique as a powerful tool to determine the nature and extent of coke accumulation in industrially-relevant zeolite catalysts.

B. Liu
D. R. Slocombe
P. P. Edwards
ResearchOpen Access11 Sept 2017
Nature Communications

Volume: 8, P: 1-7
Allogeneic transplantation for CML in the TKI era: striking the right balance

Haematopoetic stem-cell transplantation (HSCT), has been the standard-of-care for eligible patients with chronic myeloid leukaemia (CML) for several decades. The development of tyrosine kinase inhibitors (TKIs) 15 years ago revolutionized the treatment of CML. For some patients, however, allogeneic HSCT remains the best treatment option. The authors of this Review discuss the current status of HSCT as a therapeutic option for CML management.

Andrew J. Innes
Dragana Milojkovic
Jane F. Apperley
Reviews17 Nov 2015
Nature Reviews Clinical Oncology

Volume: 13, P: 79-91
Gene therapy in perspective

With the successes of molecular medicine and the recent announcement of a human gene transfer protocol, the medical world is asking whether gene therapists will now deliver the goods.

D. J. Weatherall
Comments & Opinion24 Jan 1991
Nature

Volume: 349, P: 275-276
Professor John M. Goldman CML Pioneer and Journal Founder 1938–2013

J F Apperley
R P Gale
Comments & Opinion05 Feb 2014
Bone Marrow Transplantation

Volume: 49, P: 161-162
Imatinib—should we have more of a good thing?

Imatinib 400 mg has been the first-line therapy for chronic myeloid leukemia (CML) since 2001 but may have been licensed at too low a dose. A recent study compared the standard dose with higher doses in patients with newly diagnosed CML and found no difference in response rates at 12 months. But, is the devil in the detail?

Jane F. Apperley
News & Views01 Jun 2010
Nature Reviews Clinical Oncology

Volume: 7, P: 303-304
Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant

FE Chen
I Owen
M Laffan
Research01 Mar 1997
Bone Marrow Transplantation

Volume: 19, P: 491-495
Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML

SL Rahman
P Mahendra
RE Marcus
Research23 Apr 1998
Bone Marrow Transplantation

Volume: 21, P: 955-956
Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4⁺ and partial depletion of CD8⁺ lymphocytes is associated with a higher incidence of relapse

J Serrano
J Román
A Torres
Research26 Feb 1999
Bone Marrow Transplantation

Volume: 23, P: 475-482
Clonal instability preceding lymphoid blastic transformation of chronic myeloid leukemia

A Spencer
T Vulliamy
JV Melo
Research01 Feb 1997
Leukemia

Volume: 11, P: 195-201
Low-dose donor CD8⁺ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase

D Gallardo
J García-López
A Grañena
Research01 Dec 1997
Bone Marrow Transplantation

Volume: 20, P: 945-952
T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

AJ Barrett
D Mavroudis
EJ Read
Research24 Mar 1998
Bone Marrow Transplantation

Volume: 21, P: 543-551
Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation

M Michallet
M-C Perrin
E Archimbaud
Research01 Feb 1999
Bone Marrow Transplantation

Volume: 23, P: 145-150
Usefulness of detection of minimal residual disease by ‘hypermetaphase’ fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia

D Seong
S Giralt
R Champlin
Research01 Mar 1997
Bone Marrow Transplantation

Volume: 19, P: 565-570
All-trans retinoic acid potentiates the inhibitory effects of interferon α on chronic myeloid leukemia progenitors in vitro

FX Mahon
H Chahine
J Ripoche
Research01 May 1997
Leukemia

Volume: 11, P: 667-673
Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience

A Pigneux
C Faberes
J Reiffers
Research23 Jul 1999
Bone Marrow Transplantation

Volume: 24, P: 265-270
European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching

A Devergie
JF Apperley
A Gratwohl
Research01 Jul 1997
Bone Marrow Transplantation

Volume: 20, P: 11-19
Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity

A large-scale epigenome-wide association study identifies changes in DNA methylation associated with body mass index in blood and adipose tissue, and correlates DNA methylation sites with high risk of incident type 2 diabetes.

Simone Wahl
Alexander Drong
John C. Chambers
Research21 Dec 2016
Nature

Volume: 541, P: 81-86
t(3;21) following peripheral blood stem cell transplantation in chronic phase chronic myeloid leukaemia

A Jacob
M Griffiths
J Holmes
Research01 Jun 1997
Bone Marrow Transplantation

Volume: 19, P: 1255-1258
Safety of retroviral gene marking with a truncated NGF receptor

C. Bonini
M. Grez
C. Bordignon
Correspondence01 Apr 2003
Nature Medicine

Volume: 9, P: 367-369
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

S G O'Brien
P Meinhardt
T Fischer
ResearchOpen Access11 Nov 2003
British Journal of Cancer

Volume: 89, P: 1855-1859
Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation

S Dermime
D Mavroudis
AJ Barrett
Research01 May 1997
Bone Marrow Transplantation

Volume: 19, P: 989-999
Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD)

FJ Child
R Ratnavel
R Russell-Jones
Research07 May 1999
Bone Marrow Transplantation

Volume: 23, P: 881-887
How should corticosteroids be used in the treatment of acute GVHD

T Ruutu
J Hermans
JF Apperley
Correspondence10 Sept 1998
Bone Marrow Transplantation

Volume: 22, P: 614-615
Chronic myeloid leukemia in first chronic phase not responding to α-interferon: outcome and prognostic factors after autologous transplantation

J-M Boiron
J-Y Cahn
J Reiffers
Research23 Jul 1999
Bone Marrow Transplantation

Volume: 24, P: 259-264
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line

P S Mackie
J L Fisher
P F M Choong
ResearchOpen Access03 Apr 2001
British Journal of Cancer

Volume: 84, P: 951-958
Paranasal sinusitis following allogeneic bone marrow transplant

DG Savage
P Taylor
JM Goldman
Research01 Jan 1997
Bone Marrow Transplantation

Volume: 19, P: 55-59
High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS

I Plavec
M Agarwal
E Böhnlein
Research01 Feb 1997
Gene Therapy

Volume: 4, P: 128-139
Prevention of graft-versus-host disease in high risk patients by depletion of CD4⁺ and reduction of CD8⁺ lymphocytes in the marrow graft

C Herrera
A Torres
F Martinez
Research26 Feb 1999
Bone Marrow Transplantation

Volume: 23, P: 443-450
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

An adult infected with HIV-1 who underwent allogeneic haematopoietic stem-cell transplantation for Hodgkin’s lymphoma using cells from a CCR5Δ32/Δ32 donor achieved full remission of HIV-1 for 18 months after transplantation and 16 months after cessation of antiretroviral therapy.

Ravindra K. Gupta
Sultan Abdul-Jawad
Eduardo Olavarria
Research05 Mar 2019
Nature

Volume: 568, P: 244-248
COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Dragana Milojkovic
Catherine J. Reynolds
Rosemary J. Boyton
ResearchOpen Access17 Dec 2022
Leukemia

Volume: 37, P: 244-247
Bisphosphonates induce apoptosis in human breast cancer cell lines

S G Senaratne
G Pirianov
K W Colston
ResearchOpen Access21 Mar 2000
British Journal of Cancer

Volume: 82, P: 1459-1468
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

J S Khorashad
M Anand
J Kaeda
Research09 Feb 2006
Leukemia

Volume: 20, P: 658-663
A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation

R Stocchi
R Szydlo
K N Ward
Research23 Mar 1999
Bone Marrow Transplantation

Volume: 23, P: 705-709
Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London – 2005

R F Duarte
D Pamphilon
J M Goldman
News & Views03 May 2006
Bone Marrow Transplantation

Volume: 37, P: 901-908
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Matjaz Sever
Joanna Drozd-Sokolowska
Donal P. McLornan
Research12 Nov 2024
Bone Marrow Transplantation

Volume: 60, P: 211-219
Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome

V Runde
T de Witte
J Apperley
Research05 Mar 1998
Bone Marrow Transplantation

Volume: 21, P: 255-261
Survey on haematopoietic stem cell transplantation for children in Europe

M Miano
R Cancedda
G Dini
Research06 Apr 2005
Bone Marrow Transplantation

Volume: 35, P: S3-S8
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy

Andrew J. Innes
Chloe Hayden
Dragana Milojkovic
ResearchOpen Access17 Sept 2024
Leukemia

Volume: 38, P: 2443-2455
Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey

R Arnold
T de Witte
JF Apperley
Research18 Jun 1998
Bone Marrow Transplantation

Volume: 21, P: 1213-1216
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

A Hochhaus
M Baccarani
H M Kantarjian
Research10 Apr 2008
Leukemia

Volume: 22, P: 1200-1206
Autologous/syngeneic stem cell transplantation to treat refractory GvHD

J R Passweg
K Orchard
J Mehta
Research18 Oct 2004
Bone Marrow Transplantation

Volume: 34, P: 995-998

Previous page
page 1
page 2
page 3
Next page

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2026 Springer Nature Limited